Teacher Retirement System of Texas raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 591,783 shares of the biopharmaceutical company’s stock after acquiring an additional 8,698 shares during the period. Teacher Retirement System of Texas’ holdings in Gilead Sciences were worth $41,886,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of GILD. Keel Point LLC boosted its position in shares of Gilead Sciences by 0.4% during the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 11 shares during the period. West Oak Capital LLC boosted its position in shares of Gilead Sciences by 0.7% during the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 32 shares during the period. First Heartland Consultants Inc. boosted its position in shares of Gilead Sciences by 0.4% during the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 39 shares during the period. Arrow Financial Corp boosted its position in shares of Gilead Sciences by 0.3% during the second quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock worth $1,258,000 after buying an additional 45 shares during the period. Finally, Westover Capital Advisors LLC boosted its position in shares of Gilead Sciences by 0.8% during the first quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company’s stock worth $378,000 after buying an additional 46 shares during the period. Institutional investors own 73.98% of the company’s stock.

In other Gilead Sciences news, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.86, for a total transaction of $5,563,041.38. Following the completion of the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $242,749,648.34. The disclosure for this sale can be found here. Insiders sold a total of 486,819 shares of company stock valued at $39,298,919 in the last three months. Insiders own 1.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/10/13/teacher-retirement-system-of-texas-raises-holdings-in-gilead-sciences-inc-gild.html.

Several equities analysts have recently issued reports on the company. BidaskClub downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price objective for the company in a research report on Friday. Mizuho restated a “buy” rating on shares of Gilead Sciences in a research report on Friday, September 29th. Deutsche Bank AG restated a “buy” rating and issued a $81.00 target price (up from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Finally, Leerink Swann upped their target price on Gilead Sciences from $87.00 to $89.00 and gave the stock a “market perform” rating in a research report on Thursday, October 5th. Twelve equities research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $85.96.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at 81.30 on Friday. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The stock’s 50 day moving average is $82.03 and its 200-day moving average is $72.08. The firm has a market cap of $106.17 billion, a price-to-earnings ratio of 8.83 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s revenue was down 8.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.08 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post $8.75 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 28th. Shareholders of record on Friday, September 15th were issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date of this dividend was Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.